Basic & Clinical Medicine ›› 2007, Vol. 27 ›› Issue (8): 891-894.

• 研究论文 • Previous Articles     Next Articles

Polyvinylpyrrolidone combined with Adriamycin inhibit bladder cancer cell line T24 and prevent tumor recurrence in bladder cancer patients

Zi-hua Han Tian-ji Wang Zhi-liang Weng Zhi-xian Yu Xiu-ling Wu Cheng-di Li   

  • Received:2006-04-06 Revised:2006-08-28 Online:2007-08-25 Published:2007-08-25
  • Contact: Zi-hua Han

Abstract: Objective To explore the fuction of polyvinylpyrrolidone(PVP) and Adriamycin(ADM) on human bladder cancer cell line T24 and its effects of preventing recurrence of superficial bladder cancer. Methods Cell Suppression rates were treated by MTT assay. Adhesive attraction and cell cycle were measured by flow cytometry. 231 postoperative cases with superficial bladder cancer received intravesical instillation with ADM combined with PVP (experiencial group) or NS (control group). Results Cell Suppression rates were 15.11% and 49.57%, when treated with 2.5% PVP for 24 and 72h respectively; the rates increased to 35.42% and 79.66%, when treated with 7.5%PVP. Cell Suppression rate for ADM alone was 39.05%, while co-treated with 2.5% and 7.5%PVP for 48h, the rates increased to 68.51% and 88.39% respectively. 5%PVP significantly blocked the cell cycle progression, decreased G0/G1 phase and increased G2/M phase. Adhesive attraction to T24 cell was significantly increased when treated with 5%PVP. 194 cases were followed up. Compared with control group recurrence rate was clearly decreased (60.0% vs 18.6%, P<0.01) and recurrence time was remarkly delayed (58.8m vs 20.8m, P<0.01) in experiencial group. Conclusions PVP could inhibit human bladder cancer T24 cell growth by inducing cell cycle arrest at G2/M phase and improving adhesive action, the effect could be increased by co-treated with ADM. Intravesical instillation of PVP and ADM is effective for preventing tumor recurrence with fewer side effects.